Corcept Therapeutics Q3 2026 Earnings Conference Call - CORCEPT THERAPEUTICS INC

Explicit Guidance:

• Reiterated full-year 2026 revenue guidance range of $1.1 billion to $1.2 billion, citing strength in both endocrinology and oncology segments despite not raising the upper bound.

Business-Segment Outlook:

• Cushing Syndrome: Expects the current business to generate at least $2 billion in annual revenue by the end of the decade (2030). Anticipates faster growth to a range of $3 billion to $5 billion by 2030 upon availability of the drug Reliquarolent.
• Oncology (Platinum-Resistant Ovarian Cancer): Projects Lithioly to generate more than $1 billion in annual revenue. Expects continued market share growth and positioning as the market leader.
• Market Expansion: Anticipates the number of patients treatable with Reliquarolent could increase five-fold if successful results are achieved across additional solid tumor indications (endometrial, pancreatic, prostate) and earlier lines of therapy.

Market and Competitive Outlook:

• Cushing Syndrome: Foresees a paradigm shift in diagnosis and treatment driven by the inclusion of Catalyst findings in the American Diabetes Association's 2026 consensus report and the American Association of Clinical Endocrinology's March guidance, leading to increased screening for hypercortisolism in patients with difficult-to-control diabetes.
• Oncology: Believes GR antagonism can treat any solid tumor expressing the glucocorticoid receptor in combination with any anti-cancer agent. Anticipates Lithioly's role evolving to include earlier treatment lines in the platinum-resistant setting (e.g., in combination with nab-paclitaxel and bevacizumab) due to observed benefits in progression-free and overall survival in the BELLA trial.
• Competitive Landscape: Maintains that despite emerging competitors (e.g., GenMab/Rena-S), Lithioly's unique mechanism of action (modulating immune system and increasing chemotherapy sensitivity) and ability to be combined with other agents (chemotherapy, ADCs, immunotherapy) will secure its long-term relevance.

Macro / Industry Outlook:

• Regulatory Catalysts: Highlights the December 17th PDUFA date for the resubmission of Reliquarolent for Cushing Syndrome as a critical near-term event; management is awaiting the FDA decision without predicting timing of approval beyond the date.
• Clinical Guidelines: Anticipates ongoing data from BELLA, TRIDENT, and Synergy trials to become NCCN guideline-enabling and inform future development decisions by the end of next year.
• Disease Awareness: Views hypercortisolism as significantly more prevalent than previously understood, with a structural shift in clinical practice toward screening and treatment expected over the next decade.

Strategic Initiatives:

• Reliquarolent Launch: Plans to launch Reliquarolent in Cushing Syndrome upon FDA approval, focusing primarily on treatment-naive patients rather than switching existing patients from Corlin due to the vast underserved market identified by Catalyst data.
• Phase II/III Expansion:
  • MASH: Initiating a Phase II trial at the start of the next year to evaluate 100 mg daily dosing (3 weeks on, 1 week off) of Miracorlin to maximize liver fat reduction and fibrosis improvement while monitoring ALT levels; aims to conclude the study in the second half of the year to guide Phase III entry.
  • ALS: Plans to begin a Phase III study for a cortisol modulator in ALS patients next year following positive Phase II DASL trial results showing reduced early mortality.
  • Oncology Combinations:
    • BELLA Trial (Endometrial Cancer): Enrollment nearing completion; study to determine efficacy in platinum-sensitive ovarian cancer (a earlier stage).
    • TRIDENT Trial: Evaluating Reliquarolent as a first-line treatment for pancreatic cancer.
    • Synergy Study: Phase 1b study of Nanocortlandt (GR antagonist) plus Nabolimab (PD-1 inhibitor) in solid tumors; results expected by end of next year.
    • Prostate Cancer: Collaboration with University of Chicago enrolling a Phase II trial of Reliquarolent plus Enzalumide for early-stage prostate cancer; results expected by end of next year.
• R&D Focus: Commitment to evaluating Reliquarolent and Relacoralin in combination with immunotherapy, ADCs, and chemotherapeutic agents to broaden the treatable patient population.

Risks and Headwinds to Outlook:

• Regulatory Risk: Approval of Reliquarolent is pending FDA decision on December 17th; no guarantee of approval or specific labeling outcomes (e.g., regarding liver injury signals) is provided.
• Development Risk: Future growth and patient population expansion depend on successful results from multiple ongoing Phase II and Phase III trials (BELLA, TRIDENT, Synergy, ALS Phase III, MASH Phase II); failure in these studies could negate the projected five-fold increase in treatable patients.
• Execution Risk: Reliquarolent's market success relies on incorporation of new screening guidelines into standard medical practice, which may take time.
• Pricing/Cost: While not explicitly quantified, management acknowledges the need to balance dose optimization (higher doses for efficacy) with safety profiles (minimizing ALT rises) to ensure commercial viability.

Management Tone on the Future:

• Confidence: Expressed high confidence in reaching $1 billion in annual revenue from Lithioly and $2–$5 billion from the Cushing syndrome franchise by 2030.
• Optimism: Described the current environment as an "exciting time" for the endocrinology division and highlighted the "enormous potential" of the GR antagonism platform across multiple disease states.
• Strategic Shift: Tone indicates a strategic pivot toward broader disease indications (solid tumors, MASH, ALS) where cortisol modulation offers a differentiated mechanism of action, viewing the current success in ovarian cancer and Cushing syndrome as just the "first steps."
• Cautions: Standard legal disclaimers regarding forward-looking statements; no specific hedges provided against the guidance numbers other than acknowledging the "probabilistic" nature of results.

Miscellaneous:

• Cash & Capital Allocation: Reported $662 million in cash and investments as of September 30, 2026; acquired $44 million of common stock in Q3.
• Personnel: Justin Gunn assumed the role of President of the Endocrinology Division effective October 2026; prior experience includes VP of Sales for Oncology.
• Financial Performance Context: Q3 2026 revenue was $340.5 million (up 33% QoQ, 64% YoY); Q3 net income was $126.8 million.